Number | Question |
---|---|
1 | In infants presenting to hospital what factors in history and physical examination contribute to a differential diagnosis of bronchiolitis? |
2 | In infants presenting to hospital with bronchiolitis, what are the risk factors for admission or severe disease (e.g. prolonged length of hospital stay, intensive care unit (ICU) admission, and death)? |
3 | In infants presenting to hospital or hospitalised with bronchiolitis, does performing a CXR beneficially change medical management or clinically relevant end-points? |
4 | In infants presenting to hospital or hospitalised with bronchiolitis, does performing laboratory tests (blood and/or urine) beneficially change medical management or clinically relevant end-points? |
5 | In infants presenting to hospital or hospitalised with bronchiolitis, does performing virological investigations beneficially change medical management or clinically relevant end-points? |
6 | For infants presenting to hospital or hospitalised with bronchiolitis, does use of a bronchiolitis scoring system beneficially change medical management or clinically relevant end-points? |
7 | For infants presenting to hospital or hospitalised with bronchiolitis, what criteria should be used for safe discharge? |
8a. i) | In infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points? |
8a. ii) | In older infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points? |
8b. i) | In infants presenting to hospital or hospitalised with bronchiolitis, with a personal or family history of atopy, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points? |
8b. ii) | In older infants presenting to hospital or hospitalised with bronchiolitis, with a second or subsequent episode/s of bronchiolitis or wheeze, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points? |
9 | In infants presenting to hospital or hospitalised with bronchiolitis, does administration of adrenaline / epinephrine (nebulisation, IM or IV) improve clinically relevant end-points? |
10 | In infants presenting to hospital or hospitalised with bronchiolitis, does administration of nebulised hypertonic saline improve clinically relevant end-points? |
11a. | In infants presenting to hospital or hospitalised with bronchiolitis, does administration of systemic or local glucocorticoids (nebulisation, oral, IM or IV) improve clinically relevant end-points? |
11b. | In infants presenting to hospital or hospitalised with bronchiolitis, with a positive response to Beta2 Agonists, does administration of systemic or local glucocorticoids (nebulisation, oral, IM or IV) improve clinically relevant end-points? |
11c. | In infants presenting to hospital or hospitalised with bronchiolitis, does administration of the combination of systemic or local glucocorticoids (nebulisation, oral, IM or IV) and adrenaline improve clinically relevant end-points? |
12a. | In infants presenting to hospital or hospitalised with bronchiolitis, does administration of supplemental oxygen improve clinically relevant end-points? |
12b. | In infants presenting to hospital or hospitalised with bronchiolitis, what level of oxygen saturation should lead to commencement or discontinuation of supplemental oxygen to improve clinically relevant end-points? |
13. | In infants hospitalised with bronchiolitis does continuous monitoring of pulse oximetry beneficially change medical management or clinically relevant end-points? |
14. | In infants hospitalised with bronchiolitis does the use of heated humidified high flow oxygen, or air, via nasal cannula improve clinically relevant end-points? |
15. | In infants hospitalised with bronchiolitis, does chest physiotherapy improve clinically relevant end-points? |
16a. | In infants hospitalised with bronchiolitis, does suctioning of the nose or nasopharynx improve clinically relevant end-points? |
16b. | In infants hospitalised with bronchiolitis, does deep suctioning in comparison to superficial suctioning beneficially improve clinically relevant end-points? |
17 | In infants hospitalised with bronchiolitis, does the use of nasal saline drops improve clinically relevant end-points? |
18. | In infants hospitalised with bronchiolitis, does the use of bubble CPAP improve clinically relevant end-points? |
19. | In infants hospitalised with bronchiolitis, is provision of home oxygen a safe alternative for management? |
20a. | In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication improve clinically relevant end-points? |
20b. | In infants presenting to hospital or hospitalised with bronchiolitis, does the use azithromycin medication improve clinically relevant end-points? |
20c. | In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication in infants who are at risk of developing bronchiectasis, improve clinically relevant end-points? |
21a. | In infants presenting to hospital or hospitalised with bronchiolitis, does the use of non-oral hydration improve clinically relevant end-points? |
21b. | In infants presenting to hospital or hospitalised with bronchiolitis, what forms of non-oral hydration improve clinically relevant end-points |
21c. | In infants presenting to hospital or hospitalised with bronchiolitis, does limiting the volume of non-oral hydration impact on clinical relevant end-points? |
22 | In infants presenting to hospital or hospitalised with bronchiolitis, do infection control practises improve clinically relevant end-points? |